ClinicalTrials.gg
Not yet recruitingNCT07598110FT-RIC-HAPLOUpdated May 20, 2026

FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

A Phase 2 interventional study of fludarabine and treosulfan in Acute Myeloid Leukemia, sponsored by Institut Paoli-Calmettes. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Institut Paoli-Calmettes · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 191 studies testing fludarabine in Leukemia, Myeloid, Acute — 34 open to participants now, 49 under way, 4 of them phase 3. fludarabine · Leukemia, Myeloid, Acute.

Planned enrollment
53rd of 188
77 · median 47
Started
2026
with 9 others
Phase 2
96 of 191
20 open now
Primary completion
2030-10
later than 43 of 48 live
Registered
183rd of 191
by date

Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, this one is the 53rd largest by planned enrollment of the 188 interventional ones that give a count, is one of 10 that started in 2026, is one of 96 in phase 2, reaches primary completion later than 43 of the 48 other live ones, and was the 183rd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

34 of the 191 studies testing fludarabine in Leukemia, Myeloid, Acute are open now, in 4 countries. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 34 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies testing fludarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) predominantly affect older adults, and their incidence continues to rise with advanced age. For many patients, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option capable of providing long-term disease control through the graft-versus-leukemia (GVL) effect. Historically, however, allo-HSCT was rarely offered to patients older than 50 years because of the high morbidity and mortality associated with myeloablative conditioning regimens and limited supportive care strategies. Over the past two decades, advances in reduced-intensity conditioning (RIC), infection prophylaxis, and donor availability have profoundly transformed the landscape, allowing increasing numbers of older patients to access transplantation.

Multiple studies have demonstrated that allo-HSCT confers a survival benefit in older AML patients in complete remission compared with consolidation chemotherapy alone.

The intensity of conditioning profoundly influences both relapse risk and non-relapse mortality (NRM). myeloablative conditioning (NMAC) regimens are attractive for older adults due to their low toxicity but rely solely on the immunologic GVL effect and thus carry a higher relapse risk. Reduced-intensity conditioning (RIC) regimens, incorporating intermediate-dose alkylating agents such as busulfan, melphalan, or thiotepa, offer stronger anti-leukemic effect but at the cost of greater toxicity.

These observations underscore the central question: can a conditioning regimen combine strong anti-leukemic potency with the low toxicity required for older patients undergoing Haplo-SCT? The main objective is to evaluate the efficacy of FT-RIC regimen before Haplo-SCT for older and/or frail patients diagnosed with AML, who are not eligible for a myeloablative conditioning (MAC) regimen.

To achieve this objective, the investigators will assess Progression Free Survival (PFS) defined as the time from allo-HSCT to AML relapse or death.

This is a Multicenter trial, single arm prospective of phase II. Once the conditioning has been administered and the transplant performed, the patient will receive standard routine follow-up care, with the addition of questionnaires, and for patients followed at the Institut Paoli Calmettes only, blood samples will be collected.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with age between 60 and 75 years old ; or aged 18-59 years if considered by the investigator for any reason as ineligible for MAC regimen (as defined by the EBMT criteria17), notably in case of HCT-CI ≥ 3 (patients planned by the investigators to receive a RIC regimen in clinical routine practice);
  • Patients with AML according to the ELN2022 classification criteria requiring including the MDS/AML sub category);
  • Less than 5% bone marrow blast at the time of inclusion (i.e. CR, CRi, CRh, or MLFS after prior treatment, according to ELN 2022);
  • Allo-HSCT planed with a haploidentical donor;
  • Covered by a Healthcare System;
  • Signed obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  • Left ventricular function \< 40% ;
  • Renal clearance \< 50 mL/min ;
  • Any severe uncontrolled medical condition considered by the investigator as a for using treosulfan;
  • Pregnant women or those who may become pregnant (without effective ) or breastfeeding;
  • Adults under legal protection (guardianship, curatorship, or judicial protection);
  • Inability to comply with the medical follow-up of the trial for geographical, social, or psychological reasons.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (estimated)

Study arms

  • Experimental
    fludarabine and treosulfan

    After screening and inclusion, patients will be given a RIC regimen based on the market-approved association of fludarabine and treosulfan (FT-RIC): * Fludarabine (concentrate for solution for injection/infusion) is a marketed purine analogue and antineoplastic agent. * Treosulfan (powder for solution for infusion) is a marketed alkylating medication

    Drug: fludarabine and treosulfan

Interventions

  • Drugfludarabine and treosulfan

    Drug pages: FludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TreosulfanStudies of TreosulfanTreosulfan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per standard practices, patients will be hospitalized during the treatment period. The treatment is administered by the nurses of the department under the responsibility of the investigator.Fludarabine (30 mg/m²/day from day-6 to day-2), iv andTreosulfan (10 g/m²/day from day-4 to day-2), iv

06

What researchers measure

Primary outcomes

  1. The main objective is to evaluate the efficacy of FT-RIC regimen before Haplo-SCT for older and/or frail patients diagnosed with AML, who are not eligible for a MAC regimen.

    Progression Free Survival (PFS) defined as the time from allo-HSCT to AML relapse or death

    Time frame: through study completion an average of 4 years

Secondary outcomes

  1. To evaluate adverse events related to the FT combination according to CTCAE V6.0

    Conditioning related toxicity according to CTCAE V.6.0

    Time frame: through study completion an average of 4 years

  2. To evaluate engraftment after FT-RIC

    rate of graft failure

    Time frame: through study completion an average of 4 years

  3. To evaluated hematological recovery after FT-RIC

    Cumulative incidence of neutrophil and platelet recovery

    Time frame: after hematological recovery

  4. to evaluate incidence of both acute and chronic GVHD after FT-RIC

    Cumulative incidence of acute GVHD and Cumulative incidence of chronic GVHD

    Time frame: through study completion an average of 4 years

  5. To evaluate survival, non-relapse mortality and cause of death after FT-RIC

    Probability of Overall Survival and Probability of GVHD

    Time frame: through study completion an average of 4 years

  6. To evaluate the immunosuppressive therapy duration after FT-RIC

    Prevalence of immunosuppressive therapy (IST) and GVHD at 3, 6, 9, 12 months

    Time frame: through study completion an average of 4 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2030, 48 months later.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 48 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
May 20, 2026
StartEst.
Oct 10, 2026
Primary completionEst.
Oct 10, 2030
CompletionEst.
Feb 10, 2031
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07598110
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Oct 10, 2030 (estimated)
Completion
Feb 10, 2031 (estimated)
Last update
May 20, 2026

Study contacts

PAKRADOUNI Jihane
Contact
pakradounij@ipc.unicancer.fr
0491223824
ARTHUR Allison
Contact
arthura@ipc.unicancer.fr
0491223448

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Treosulfan

Start the discussion